Have a feature idea you'd love to see implemented?
Let us know!
AYTU Aytu Biopharma Inc
Price (delayed)
$2.2
Market cap
$13.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.86
Enterprise value
$8.65M
Highlights
The company's debt fell by 9% QoQ and by 8% YoY
Aytu Biopharma's gross margin has increased by 9% YoY and by 3.2% from the previous quarter
AYTU's EPS is up by 44% YoY but it is down by 17% QoQ
Aytu Biopharma's quick ratio has increased by 19% from the previous quarter but it has decreased by 7% YoY
Aytu Biopharma's equity has decreased by 30% YoY and by 10% QoQ
AYTU's revenue is down by 25% YoY and by 14% QoQ
Key stats
What are the main financial stats of AYTU
Market
Valuations
Earnings
Shares outstanding
6.15M
Market cap
$13.53M
Enterprise value
$8.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
0.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.11
Revenue
$81M
EBIT
-$9.28M
EBITDA
-$1.01M
Free cash flow
-$1.39M
Per share
Balance sheet
Liquidity
EPS
-$2.86
Free cash flow per share
-$0.25
Book value per share
$4.98
Revenue per share
$14.63
TBVPS
$11.85
Total assets
$118.1M
Total liabilities
$90.38M
Debt
$15.13M
Equity
$27.72M
Working capital
-$337,000
Debt to equity
0.55
Current ratio
0.99
Quick ratio
0.7
Net debt/EBITDA
4.82
Margins
Efficiency
Dividend
EBITDA margin
-1.2%
Gross margin
67.4%
Net margin
-19.6%
Operating margin
-6.5%
Return on assets
-12.4%
Return on equity
-51.3%
Return on invested capital
-5,389.8%
Return on capital employed
-16.6%
Return on sales
-11.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AYTU stock price
How has the Aytu Biopharma stock price performed over time
Intraday
-6.38%
1 week
-9.47%
1 month
-9.47%
1 year
-24.4%
YTD
-22.54%
QTD
-6.38%
Financial performance
How have Aytu Biopharma's revenue and profit performed over time
Revenue
$81M
Gross profit
$54.59M
Operating income
-$5.25M
Net income
-$15.84M
Gross margin
67.4%
Net margin
-19.6%
Aytu Biopharma's operating income has plunged by 177% from the previous quarter but it has soared by 71% YoY
Aytu Biopharma's operating margin has surged by 61% YoY
The company's net margin fell by 34% QoQ and by 23% YoY
AYTU's revenue is down by 25% YoY and by 14% QoQ
Growth
What is Aytu Biopharma's growth rate over time
Valuation
What is Aytu Biopharma stock price valuation
P/E
N/A
P/B
0.44
P/S
0.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.11
AYTU's EPS is up by 44% YoY but it is down by 17% QoQ
The P/B is 33% below the 5-year quarterly average of 0.7 and 6% below the last 4 quarters average of 0.5
Aytu Biopharma's equity has decreased by 30% YoY and by 10% QoQ
AYTU's P/S is 84% below its 5-year quarterly average of 1.0 and 20% below its last 4 quarters average of 0.2
AYTU's revenue is down by 25% YoY and by 14% QoQ
Efficiency
How efficient is Aytu Biopharma business performance
AYTU's ROS is down by 40% QoQ
The ROE has contracted by 31% YoY and by 27% from the previous quarter
The ROA has contracted by 20% from the previous quarter and by 4.2% YoY
Dividends
What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AYTU.
Financial health
How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 31% higher than its total liabilities
Aytu Biopharma's quick ratio has increased by 19% from the previous quarter but it has decreased by 7% YoY
AYTU's current ratio is up by 16% from the previous quarter but it is down by 3.9% YoY
The company's debt is 45% lower than its equity
The debt to equity has grown by 31% YoY
Aytu Biopharma's equity has decreased by 30% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.